Evidence map›Paper›PMID 39247710›Full record

ArticleGastroenterology research2024

Effect of Pemafibrate on the Lipid Profile, Liver Function, and Liver Fibrosis Among Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

Mona Hassan, Hasan Al-Obaidi, Megan Karrick, Nooraldin Merza, Yusuf Nawras, Omar Saab, Ahmed Dheyaa Al-Obaidi, Fatima Merza, Hashim Talib Hashim, Khalid Al Zubaidi and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastroenterology research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Mona HassanGastroenterology and Hepatology Department, The University of Toledo, Toledo, OH, USA.
Hasan Al-ObaidiInternal Medicine Department, Jamaica Hospital Medicine Center, Queens, NY, USA.
Megan KarrickGastroenterology and Hepatology Department, The University of Toledo, Toledo, OH, USA.
Nooraldin MerzaGastroenterology and Hepatology Department, The University of Toledo, Toledo, OH, USA.
Yusuf NawrasUniversity of Toledo College of Medicine and Life Science, Toledo, OH, USA.
Omar SaabInternal Medicine Department, Cleveland Clinic, Cleveland, OH, USA.
Ahmed Dheyaa Al-ObaidiInternal Medicine Department, College of Medicine, University of Baghdad, Baghdad, Iraq.
Fatima MerzaDepartment of Health and Human Services, University of Michigan, Dearborn, MI, USA.
Hashim Talib HashimCollege of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.
Khalid Al ZubaidiInternal Medicine Department, University of Al-Mostansiryah College of Medicine, Baghdad, Iraq.
Daniah Al-SabbaghInternal Medicine Department, Al-Kindy College of Medicine, University of Baghdad, Baghdad, Iraq.
Rand MatbachiInternal Medicine Department, College of Medicine, University of Baghdad, Baghdad, Iraq.
Zainab NooriInternal Medicine Department, University of Al-Mostansiryah College of Medicine, Baghdad, Iraq.
Hajra Amatul-RaheemDeccan College of Medical Sciences, Hyderabad, Telangana, India.
Sarmad MansurGastroenterology and Hepatology Department, The University of Toledo, Toledo, OH, USA.
Omer Al NajafiInternal Medicine Department, Zucker School of Medicine, Northwell Health at Mather Hospital, Hempstead, NY, USA.
Marwah AlgodiInternal Medicine Department, Al-Kindy College of Medicine, University of Baghdad, Baghdad, Iraq.
Tamarah Al HamdanyDepartment of Health and Human Services, University of Michigan, Dearborn, MI, USA.
Abdallah KobeissyGastroenterology and Hepatology Department, The University of Toledo, Toledo, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are prevalent conditions linked to obesity and metabolic disturbances, with potential complications such as cirrhosis and cardiovascular risks. This systematic review and meta-analysis aimed to evaluate the efficacy of pemafibrate, a drug targeting fat and sugar metabolism genes, in treating patients with MASLD/MASH. Methods: Databases such as MEDLINE, Web of Science, Cochrane Library, and Scopus were searched until September 2023 to identify relevant studies. Selected studies underwent a thorough quality assessment using tools like Risk of Bias 2 tool (ROB-2) and the National Institutes of Health (NIH) Quality Assessment Tools. Comprehensive meta-analysis software was used for statistical evaluations, with a focus on lipid profiles, liver function tests, and fibrosis measurements. Results: A total of 13 studies were included; 10 of them were included in the quantitative analysis. Our findings showed that pemafibrate significantly decreased low-density lipoprotein cholesterol (LDL-C) (effect size (ES) = -9.61 mg/dL, 95% confidence interval (CI): -14.15 to -5.08), increased high-density lipoprotein cholesterol (HDL-C) (ES = 3.15 mg/dL, 95% CI: 1.53 to 4.78), and reduced triglycerides (TG) (ES = -85.98 mg/dL, 95% CI: -96.61 to -75.36). Additionally, pemafibrate showed a marked reduction in liver enzyme levels, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyl transpeptidase (GGT), and alkaline phosphatase (ALP), with significant effect sizes and P values. For liver stiffness outcomes, pemafibrate decreased AST to platelet ratio index (APRI) (ES = -0.180, 95% CI: -0.221 to -0.138). Conclusions: Pemafibrate, with its enhanced efficacy and safety profile, presents as a pivotal agent in MASLD/MASH treatment. Its lipid-regulating properties, coupled with its beneficial effects on liver inflammation markers, position it as a potentially invaluable therapeutic option.

Indexed as

Lipid profileLiver fibrosisLiver stiffnessMASHMASLDPemafibratePPAR

Identifiers

PMID39247710
PMCPMC11379042

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.